Return to Listing

2 result(s) for Selumetinib

PI Name Protocol # Title
Matthew Taylor IRB00009480 A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
Khaled Tolba IRB00011462 A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus nab-Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080